World
U.S. Pledges Up to $2.1 Billion for Sanofi, GlaxoSmithKline Covid Vaccine
- Deal marks biggest Operation Warp Speed investment yet
- European Commission moves to line up 300 million doses
This article is for subscribers only.
The Trump administration will provide as much as $2.1 billion to Covid-19 vaccine partners Sanofi and GlaxoSmithKline Plc, the biggest U.S. investment yet in fast-tracking shots and snapping up supplies.
Part of Operation Warp Speed, the funding will support clinical trials and manufacturing while allowing the U.S. to secure 100 million doses of the shot, if it’s successful, the companies said Friday. The country has an option to receive an additional 500 million doses longer term.